Executives of advanced biofuels, feedstock crop technology, and industrial biotechnology companies give an update on their progress in commercializing advanced biofuels. BIO presents principles for coordinating and enhancing existing federal policy supporting these companies’ efforts. Listen or download the program.

BIOtech Now's Tracy Krughoff speaks with Jonas Frisén of the Karolinska Institute in Stockholm, Sweden about his session on stem cells at the upcoming BIO International Convention. Listen or download the podcast.

BIOtech Now interviews Dr. Michael Rosenberg, President and CEO of Health Decisions. He discusses adaptive research methods which can streamline and improve the design of clinical trials and previews his upcoming presentation at the 2009 BIO International Convention. Listen or download the program.

CureDuchenne is a non-profit organization founded in 2003 by Debra and Paul Miller, parents of a Duchenne boy. CureDuchenne’s vision is its name to cure Duchenne muscular dystrophy. CureDuchenne aggressively seeks the most promising, leading edge research breakthroughs and expedites them to the clinical trial process. The ultimate goal…give the boys that have Duchenne now a chance to live a normal life by expediting the cure and/or the availability of therapies that can give quality of life to Duchenne boys, much like insulin does for diabetics.

Total job creation, accounting for economic multiplier effects, could reach 123,000 in 2012, 383,000 in 2016, and 807,000 by 2022.

Large-scale production of advanced biofuels beyond the level of the Renewable Fuel Standard is achievable and sustainable by 2030.

Since the commercialization of biotechnology in 1996, farmers have used this science to grow plants that yield more per acre with reduced production costs while being resistant to disease and pests and also beneficial to the environment.

In the near future, we’ll see crops that will be resistant to environmental stresses like drought and crops that use soil nutrients more efficiently, boosting productivity in areas of the world with inadequate rainfall or poor soil.

Read the fact sheet

Genetic disorders known as Lysosomal Storage Diseases, including Gaucher disease, Fabry disease and Pompe disease, continue to be an area of high unmet medical need.

In a presentation at International Science Attachés Briefing, Matthew Carr outlines how the "third wave" in biotechnology can help reduce greenhouse gas emissions.